THERAPEUTICS TO IMPROVE CARDIOVASCULAR HEALTH
Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription.
Development of Vascepa leveraged Amarin’s extensive experience in lipid sciences and the potential therapeutic benefits of polyunsaturated fatty acids. Such development challenged previously established norms to create a potent, yet safe, targeted single ingredient product in contrast to prior generation omega-3 mixtures and other prescription drugs. The use of Vascepa is now supported by over 40 granted patents and by FDA designation in 2015 of Vascepa’s active ingredient as a New Chemical Entity. This means that no prior FDA-approved drug had the active ingredient contained in Vascepa. Also, no prior drug with icosapent ethyl was ever characterized for FDA review and approved by the FDA to treat or prevent a medical condition.